Managing residual risk in patients receiving statin therapy

Omission of potential competing interests: In “Managing residual risk in patients receiving statin therapy” in the 5 April 2010 issue of the Journal (Med J Aust 2010; 192: 366-367), potential competing interests were omitted. The author, Ian Hamilton-Craig, has received financial support to attend and give presentations at scientific meetings from AstraZeneca, Merck Sharp & Dohme, Schering-Plough, Pfizer, Bristol-Myers Squibb, Solvay, Sanofi-Aventis, Novartis and Abbott Australasia. He is a member of the Lipid Advisory Board of Merck Sharp & Dohme/Schering-Plough, AstraZeneca and Solvay, the Familial Hypercholesterolaemia Committee of the Australian Atherosclerosis Society, and the Council on Genetic Cardiovascular Diseases of the Cardiac Society of Australia and New Zealand.